

DEXAMETHASONE SODIUM PHOSPHATE EYE DROPS

CLASS: Anti-inflammatory Agent, Ophthalmic; Corticosteroid, Ophthalmic; Corticosteroid, Otic

INDICATIONS: Management of steroid-responsive inflammatory conditions such as allergic conjunctivitis, iritis, or cyclitis; symptomatic treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The ophthalmic solution is also indicated for otic use to treat steroid-responsive inflammatory conditions of the external auditory meatus.

Ophthalmic intravitreal implant (Ozurdex®): Treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO); treatment of noninfective uveitis

AVAILABLE DOSAGE FROM THE HOSPITAL:

DEXAMETHASONE SODIUM PHOSPHATE EYE DROPS

TRADE NAMES:

DOSAGE:

- **Dosing: Adult**
 - **Anti-inflammatory:**
Ophthalmic:

Solution: Instill 1-2 drops into conjunctival sac every hour during the day and every other hour during the night; gradually reduce dose to 1 drop every 4 hours, then to 3-4 times/day

Suspension: Instill 1-2 drops into conjunctival sac up to 4-6 times/day; may use hourly in severe disease; taper prior to discontinuation

Otic:

Solution: Initial: Instill 3-4 drops into the aural canal 2-3 times a day; reduce dose gradually once a favorable response is obtained. Alternately, may pack the aural canal with a gauze wick saturated with the solution; remove from the ear after 12-24 hours. Repeat as necessary.

Macular edema (following BRVO or CRVO): Ocular implant (Ozurdex®):
Intravitreal injection: 0.7 mg implant injected in affected eye

Noninfective uveitis: Ocular implant (Ozurdex®): Intravitreal injection: 0.7 mg implant injected in affected eye

- **Dosing: Geriatric** :Refer to adult dosing. Solution/suspension: Use cautiously in the elderly in the smallest possible dose
- **Dosing: Renal Impairment**
No dosage adjustment provided in manufacturer's labeling
- **Dosing: Hepatic Impairment**
No dosage adjustment provided in manufacturer's labeling

COMMON SIDE EFFECT: Intravitreal implant (Ozurdex®):

>10%: Ocular: Intraocular pressure increased (25%), conjunctival hemorrhage (22%)

PREGNANCY RISK FACTORS: C